Would you consider PD-L1 score when deciding whether to incorporate durvalumab in first-line metastatic biliary cancer?

There are no biomarkers that I currently recommend to select patients for durvalumab in first-line metastatic biliary cancer. In subgroup analysis, there appears to be benefit to durvalumab in first-line metastatic biliary tract cancer regardless of PDL1 expression. Therefore, I would not consider P...

I do not, no clear benefit shown based on PDL1 status.